Join us on December 9th at the American Society of Hematology’s annual meeting where we’ll be presenting preclinical data from our p300 KAT inhibitor program for #multiplemyeloma. Learn more here: https://bit.ly/4hxqLb3
Kronos Bio
Biotechnology Research
San Mateo, California 9,443 followers
We’re focused on creating a world where no life is cut short by cancer or other serious diseases.
About us
Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. At Kronos Bio, we have two molecules that have emerged from our product engine. KB-0742, our CDK9 inhibitor, is being evaluated in a phase 1/2 clinical trial as a treatment for patients with MYC-dependent tumors such as triple negative breast cancer, non-small cell lung cancer and ovarian cancer, as well as patients with transcription factor fusion-driven cancers and other transcriptionally addicted cancers including chordomas, sarcomas and small cell lung cancer. Our new development candidate, KB-9558, targets the KAT domain of p300, a critical node of the IRF4 TRN, which is a core oncogenic transcription program that drives multiple myeloma. Additionally, Kronos Bio began a discovery collaboration with Genentech in January 2023. Our companies are working together to advance novel therapies against transcriptional targets in oncology. For additional information about our community guidelines, visit: https://bit.ly/3FfcDQW.
- Website
-
http://www.kronosbio.com
External link for Kronos Bio
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Mateo, California
- Type
- Public Company
- Founded
- 2017
Locations
-
Primary
Get directions
1300 S El Camino Real
Suite 400
San Mateo, California 94402, US
-
Get directions
301 Binney St.
2nd Floor East
Cambridge, Massachusetts 02142, US
Employees at Kronos Bio
Updates
-
At Kronos Bio, we believe it’s important to find ways to give back to our local communities. Our team was fortunate to volunteer with Cradles to Crayons, Drumlin Farm, and Samaritan House of San Mateo County throughout October to help in the fight against clothing insecurity, unsustainable farming, and poverty. A core value for us is strengthening the bonds with those around us and creating positive change in and outside of the lab, so join us in making an impact and uplifting those around you! https://lnkd.in/gQfVZa2w
-
-
Check out today’s press release and preclinical poster presentation highlighting the importance of p300 KAT inhibition in HPV-driven tumors at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on October 24th at 9:00 AM CEST. Learn More: https://bit.ly/3BUGaSp
-
Today, we’re celebrating Indigenous People’s Day as a way to raise awareness of Indigenous voices and recognize the invaluable contributions these communities continue to make in creating a more inclusive tomorrow. #IndigenousPeoplesDay
-
-
We’re presenting preclinical data from our p300 KAT inhibitor program for human papillomavirus (HPV)-driven tumors at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on October 24th at 9:00 am CEST. Join us in learning how our program may provide innovative targeted therapies against HPV-driven cancers. Learn more here: https://bit.ly/4dHHx4f #ENASymp24
-
-
Happy Hispanic Heritage Month! Join Kronos Bio in honoring the importance of the rich history and diversity that Hispanic communities bring to help shape the fields of science and technology and we will continue to celebrate their achievements. #HispanicHeritageMonth
-
-
Today we announced the selection of KB-7898, a p300 KAT inhibitor, our first development candidate for #autoimmunediseases, for the potential treatment of #Sjögrensdisease, a chronic #autoimmunedisease marked by the production of autoantibodies, ongoing inflammation and lymphocytic infiltration of the exocrine glands which may lead to uncomfortable dryness symptoms, known as sicca. Preclinical data will be presented at #ACRConvergence2024. Learn more: https://bit.ly/4eB3O54
-
We’re so grateful to have the opportunity to listen firsthand to the insightful sessions at OCRA’s Virtual International Gynecologic Cancer Conference. Special thanks to the organizers and speakers for their hard work in making it such a meaningful experience and your ongoing support of patients in need. #OCRA #CancerResearch #UniteForHope #ocrahope #ovariancancer
Ovarian cancer survivors shared advice for managing scanxiety, chemo treatments and more during a compelling online conference session today.
-
We were incredibly honored to participate in National Ovarian Cancer Coalition’s Together in Teal Walk in Boston. The strength and passion of everyone there was inspiring. Together, we walked in solidarity to raise awareness and support the mission to end #ovariancancer. A huge thank you to everyone who came together! #KnowOvarian #OvarianCancerAwarenessMonth #TogetherInTeal
-
-
We announced today that an oral presentation of preclinical data to support p300 KAT inhibition as an approach to anti-inflammatory therapy for #autoimmune diseases will take place at the American College of Rheumatology Convergence 2024 on Monday, November 18th at 4:15 p.m. EST. Learn more here: https://bit.ly/3ZBSfWo #ACR24
-